Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study

Rektorová, I.; Rektor, I.; Bareš, M.; Dostál, V.; Ehler, E.; Fanfrdlová, Z.; Fiedler, J.; Klajblová, H.; Kulišt’ák, P.; Ressner, P.; Svátová, J.; Urbánek, K.; Velísková, J.

doi:10.1046/j.1468-1331.2003.00612.x

Public

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study

Shared by NobleBlocks on Jun 19, 2003 • 12:00 AM UTC

Authors:

I. Rektorová

I. Rektor

M. Bareš

Abstract

An 8‐month multicentre prospective randomized study aimed at comparing the effects of dopamine receptor agonists pramipexole (PPX; Mirapexin®) and pergolide (PRG; Permax®) as add‐on to L‐dopa therapy on depression [Montgomery and Asberg Depression Rating Scale (MADRS)] in 41 non‐demented patients (2...

Discussions